CN110121502A - 一种抗抑郁化合物及其制备方法和应用 - Google Patents

一种抗抑郁化合物及其制备方法和应用 Download PDF

Info

Publication number
CN110121502A
CN110121502A CN201780081277.3A CN201780081277A CN110121502A CN 110121502 A CN110121502 A CN 110121502A CN 201780081277 A CN201780081277 A CN 201780081277A CN 110121502 A CN110121502 A CN 110121502A
Authority
CN
China
Prior art keywords
substituted
alkyl
aryl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780081277.3A
Other languages
English (en)
Other versions
CN110121502B (zh
Inventor
黄成钢
李扬
蒋华良
谢阳
郭飞
李志雄
陈明苍
郑明月
孙兆林
高羽
田小亭
胡培
张兵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN110121502A publication Critical patent/CN110121502A/zh
Application granted granted Critical
Publication of CN110121502B publication Critical patent/CN110121502B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

一种抗抑郁甾体化合物及其制备方法和应用，该化合物的结构如式(I)所示，其中各取代基的定义如说明书和权利要求书所述。本发明的化合物可以用于防护、处理、治疗或减轻抑郁症等多种疾病、病症。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201780081277.3A 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用 Active CN110121502B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611260514.6A CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
CN2016112605146 2016-12-30
PCT/CN2017/120134 WO2018121770A1 (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN110121502A true CN110121502A (zh) 2019-08-13
CN110121502B CN110121502B (zh) 2022-09-23

Family

ID=62707894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611260514.6A Pending CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用
CN201780081277.3A Active CN110121502B (zh) 2016-12-30 2017-12-29 一种抗抑郁化合物及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611260514.6A Pending CN108264535A (zh) 2016-12-30 2016-12-30 一种抗抑郁化合物及其制备方法和应用

Country Status (5)

Country Link
US (1) US11142543B2 (zh)
EP (1) EP3564253A4 (zh)
JP (1) JP6901569B2 (zh)
CN (2) CN108264535A (zh)
WO (1) WO2018121770A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109988218B (zh) * 2017-12-29 2022-11-25 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用
CN109206472A (zh) * 2018-09-27 2019-01-15 华东理工大学 薯蓣皂苷元衍生物、其药物组合物及其应用
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
WO2020259612A1 (zh) * 2019-06-26 2020-12-30 中国科学院上海药物研究所 一种抗抑郁甾体化合物
CN113831381A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种用于治疗抑郁症的甾体化合物
CN113831382A (zh) * 2020-06-24 2021-12-24 中国科学院上海药物研究所 一种甾体化合物
CN113292629B (zh) * 2021-06-21 2022-04-26 西南民族大学 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用
WO2023155757A1 (zh) * 2022-02-18 2023-08-24 北京清博汇能医药科技有限公司 基于菝契皂苷元结构的衍生物及其药物组合物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051381A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
CN102924559A (zh) * 2012-11-16 2013-02-13 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
WO2015163318A1 (ja) * 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
RU2332999C2 (ru) 2002-03-27 2008-09-10 ФИТОФАРМ ПиЭлСи Терапевтические способы и применения сапогенинов и их производных
WO2005051380A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octahydroindols as antagonists of melanin concentrating hormone receptor 1 (mch1r)
US20050245495A1 (en) * 2004-04-07 2005-11-03 Chen Zhao Azacyclosteroid histamine-3 receptor ligands
EP2374455A3 (en) 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101214253B (zh) 2008-01-07 2011-09-21 中国人民解放军第二军医大学 知母皂苷b-ⅱ用于制备抗抑郁产品的用途
CA2716122A1 (en) 2008-03-05 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
CN101768202B (zh) 2009-02-18 2013-10-30 沈阳药科大学 知母中菝葜皂苷元及其衍生物的制备方法及其医药新用途
WO2019129176A1 (zh) * 2017-12-29 2019-07-04 中国科学院上海药物研究所 一种菝葜皂苷元衍生物及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051381A1 (en) * 2003-11-26 2005-06-09 Biovitrum Ab Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R)
CN102924559A (zh) * 2012-11-16 2013-02-13 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
WO2015163318A1 (ja) * 2014-04-25 2015-10-29 レジリオ株式会社 アルツハイマー病の治療剤を含む、神経細胞の軸索の機能不全が関与する疾患の治療剤

Also Published As

Publication number Publication date
EP3564253A4 (en) 2020-07-29
WO2018121770A1 (zh) 2018-07-05
JP2020503341A (ja) 2020-01-30
JP6901569B2 (ja) 2021-07-14
CN110121502B (zh) 2022-09-23
EP3564253A1 (en) 2019-11-06
US20200385418A1 (en) 2020-12-10
CN108264535A (zh) 2018-07-10
US11142543B2 (en) 2021-10-12

Similar Documents

Publication Publication Date Title
CN110121502A (zh) 一种抗抑郁化合物及其制备方法和应用
UA118280C2 (uk) Анелована гетероциклічна сполука
CN106659719B (zh) 毒蕈碱受体激动剂
EA021747B1 (ru) Опсинсвязывающие лиганды, композиции и способы использования
CN107406449A (zh) 作为毒蕈碱m1受体和/或m4受体的激动剂的螺环化合物
CN108601775A (zh) 阿片受体配体和细胞色素p450抑制剂的组合
CN107098899A (zh) 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
CA3179785A1 (en) Advantageous benzofuran compositions for mental disorders or enhancement
TWI648276B (zh) 雜環化合物
CA3182412A1 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
CN106794364A (zh) 取代的4‑苯基哌啶及其制备和用途
AU2003241903A1 (en) Piperidine derivative, process for producing the same, and use
AU2016377782B2 (en) CFTR regulators and methods of use thereof
JP2012505165A (ja) 新規なドーパミンｄ３受容体リガンド、その調製及び使用
IL301588A (en) Analogs of N-(2-(2,6-deoxypyridin-3-yl)-1,3-dioxoindolin-5-yl)arylsulfonamide are converted as cereblon protein modulators
WO2019129176A1 (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
CA3017342A1 (en) Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof
AU2016379444A1 (en) CFTR regulators and methods of use thereof
EP3394046B1 (en) Cftr regulators and methods of use thereof
CN109988218A (zh) 一种菝葜皂苷元衍生物及其制备方法和应用
EP3233799A1 (en) Dopamine d2 receptor ligands
US6107313A (en) Dopamine receptor antagonists
WO2020048043A1 (zh) 作为防治精神障碍疾病的苯胺类化合物
JP2018048093A (ja) モルヒナン誘導体及びその医薬用途
CN107540636A (zh) 一种含氮杂环衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant